RNAi药物是一类新型疗法，通过"沉默"编码与疾病相关蛋白质的信使RNA分子来发挥作用。据悉，双 方将基于圣因生物专有的LEAD™平台共同推动针对代谢性疾病的RNAi候选药物的开发。 LEAD™(Ligand and Enhancer Assisted Delivery，新型配体与增效基团协同递送)平台是圣因生物自主研 发的一种组织选择性递送技术，能够实现RNAi药物在肝外组织与细胞中的高效、特异性递送。基于该 平台，有望开发出每年仅需两次皮下给药的代谢性疾病突破性疗法。圣因生物将负责基于LEAD™平台 为双方合作项目筛选并确定最优RNAi活性分子，礼来将负责后续药物的IND申报研究、临床开发和商 业化。 智通财经APP获悉，礼来(LLY.US)上周六宣布，与圣因生物(SanegeneBio)达成一项价值最高达12亿美元 的全球研发合作与许可协议，共同开发和商业化用于代谢性疾病的RNAi疗法。 根据协议，礼来将向圣因生物支付预付款和股权投资，同时接手由圣因生物发现的RNAi分子的临床前 研究(IND申报前研究)、临床开发以及商业化工作。此外，圣因生物还有资格获得最高达12亿美元的发 现、开发、监管及商业化里程 ...

Core Viewpoint - Agna Biopharmaceuticals, a Chinese biotech company, is preparing for an IPO in Hong Kong, aiming to raise several hundred million dollars [1] Company Overview - Agna Biopharmaceuticals was established in 2021 and is headquartered in Guangzhou, Guangdong Province [1] - The company focuses on RNAi drugs and mRNA vaccines, leveraging the potential of RNA technology [1] - Agna has developed a diverse range of RNA combinations and efficient drug delivery systems targeting infectious diseases, metabolic diseases, cardiovascular diseases, malignant tumors, and rare diseases [1] Production Capacity - With support from local government, Agna Biopharmaceuticals has built an advanced production line capable of producing over 500 million doses of mRNA vaccines annually [1] IPO Details - The company is collaborating with several investment banks, including Bank of America, CICC, Jefferies, and JPMorgan, for its IPO [1] - Agna has submitted a confidential IPO application, with specific details regarding the scale and timing still under discussion [1]

Core Viewpoint - Agna Biopharmaceuticals, a Chinese biotech company, is planning an IPO in Hong Kong with potential fundraising of several hundred million dollars [1] Company Overview - Agna Biopharmaceuticals was established in 2021 and is headquartered in Guangzhou, Guangdong Province [1] - The company focuses on RNAi drugs and mRNA vaccines, leveraging the potential of RNA and its diverse RNA combinations along with efficient drug delivery systems [1] - Agna is developing RNA drugs and vaccines for infectious diseases, metabolic diseases, cardiovascular diseases, malignant tumors, and rare diseases [1] Production Capacity - With support from the local government, Agna has built an advanced production line capable of producing over 500 million doses of mRNA vaccines annually [1] IPO Details - The company is collaborating with major investment banks including Bank of America, CICC, Jefferies, and JPMorgan for its IPO [1] - Agna has submitted a confidential IPO application, with specific details regarding scale and timing still under discussion [1]